{'fraction_non_alphanumeric': 0.03564084989718986, 'fraction_numerical': 0.03015764222069911, 'mean_word_length': 5.3478260869565215, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The assessment of clinicopathological features, therapy pattern and survival benefit of 162 gastric cancers with liver metastases.

BACKGROUND/AIMS
This study investigated the influence of clinicopathological characteristics and different therapy patterns on overall survival of gastric cancer patients with liver metastases.


METHODOLOGY
One hundred and sixty two patients were enrolled in this study. The data of clinicopathological characteristics, treatment methods and overall survival were collected. Univariate and multivariate analyses were performed using log-rank tests and Cox’s proportional hazard model, respectively.


RESULTS
Of all the patients enrolled, 27 (16.7%) had liver-only metastases and 48 patients (28.7%) received local treatment for liver metastases. The median overall survival of the 162 patients was 9.5 months (95%CI: 8.4-10.6). One- and two-year survival rates were 28.4% and 4.3%, respectively. There was no difference in the overall survival of patients who had received the different chemotherapy regimens. Multivariate analysis revealed that numbers of liver metastases 1-3, without extrahepatic metastases, receiving local treatment for liver metastases were better prognostic factors, and HR were 0.490, 0.479, 0.495.


CONCLUSIONS
A smaller number of liver metastases, without extrahepatic metastases and local therapy for liver metastases are the independent survival factors for gastric cancer with liver metastases.